The close relationship between pharmacokinetic behaviour and the clini
cal efficacy of anthelmintic compounds is now well confirmed. The unde
rstanding of potential factors affecting the plasma bioavailability of
anthelmintic drug in animal production is crucial in optimizing their
use and in reducing investment in parasite control. This article desc
ribes a number of host and drug related factors that may affect pharma
cokinetic behaviour and the resultant clinical efficacy of anthelminti
c drug under field conditions.